Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes
Chia-Yu Kuo, Jheng-Yan Wu, Ya-Wen Tsai, Chih-Cheng Lai, Jiun-Ling Wang · 2026
Read Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes by Chia-Yu Kuo, Jheng-Yan Wu, Ya-Wen Tsai, Chih-Cheng Lai, Jiun-Ling Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13645759.txt.
Description
Chia-Yu Kuo and four colleagues compare the diabetes drug tirzepatide with four older drug classes on preventing diabetic foot problems, a major cause of disability in type 2 diabetes. Their records come from the TriNetX research network and cover patients who started treatment between January 2022 and July 2025. Matched groups were built so each comparison started from similar patients. The outcome combined ulcers, infections, severe circulation failure, and procedures up to amputation.
Tirzepatide users had lower foot complication rates than users of three older classes, sulfonylureas, DPP-4 inhibitors, and SGLT2 inhibitors. Against another modern drug class, GLP-1 receptor agonists, results were about the same. Each matched comparison held well over ninety thousand patients per side, which gives the pattern weight. The authors suggest the drug may be a useful choice for patients at high risk of foot ulcers or amputation, while noting the study rests on records rather than a trial.
Catalog record
| CREATOR | Chia-Yu Kuo, Jheng-Yan Wu, Ya-Wen Tsai, Chih-Cheng Lai, Jiun-Ling Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |